Andrew Dudum, the CEO of Hims & Hers Health Inc. (NYSE:HIMS), recently sold shares worth approximately $815,029, according to ...

Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), reported a significant transaction involving ...

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...

Citigroup has recently reduced Hims & Hers Health Inc (HIMS) stock to Sell rating, as announced on January 10, 2025, according to Finviz. Earlier, on January 7, 2025, BTIG Research had initiated the ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

In recent trading, Hims & Hers Health Inc (HIMS) stock price has shown some volatility, fluctuating 9.60% over the last five trades and -10.88% over the past 30 trades. This represents a notable shift ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...